Massive diarrhea from antibiotics: prevent with medicinal yeast

Massive diarrhea from antibiotics: prevent with medicinal yeast

We are searching data for your request:

Forums and discussions:
Manuals and reference books:
Data from registers:
Wait the end of the search in all databases.
Upon completion, a link will appear to access the found materials.

Resistance to antibiotics is increasing worldwide. While resistance threatens the effective therapy of large groups of patients, the undesirable effects of antibiosis burden the individual patient. Long side effects of diarrhea are common side effects.

Antibiotic-associated diarrhea (AAD) is not uncommon: According to studies, antibiotics in the outpatient area lead to diarrhea in 5 to 39 percent of cases (Szajewska H and Mrukowicz J, Aliment Pharmacol Ther 2005 Sep 1; 22 (5) 365–72), in the inpatient area this risk even exists in up to 60 percent of cases (McFarland LV, Am J Gastroenterol 2006 Apr; 101 (4): 812–22). Antibiotics cannot differentiate between pathogenic and healthy germs: they also damage the beneficial bacteria in the intestinal flora. This means that the pathogenic strains assert themselves in the intestine at the expense of the other digestive bacteria. The result: stressful diarrhea.

Medicinal products from medical yeast (Saccharomyces boulardii) have proven particularly useful in the prophylaxis and treatment of such diarrhea. The so-called motility inhibitors that are often used to treat diarrhea, on the other hand, are out of the question for the therapy of AAD, because they lead to a slower elimination of the pathogens from the body. Pathogenic germs can then multiply more easily and diarrhea can even be increased.

Such problems do not arise when using Saccharomyces boulardii. The effectiveness and good tolerability of the drug has been proven by a large number of clinical studies. For example, in a meta-analysis evaluating five clinical studies involving a total of 1,076 patients, treatment with Saccharomyces boulardii showed significant efficacy compared to placebo. The risk of an AAD has decreased from 17.2 percent to 6.7 percent, which corresponds to a reduction of 61 percent. (Szajewska H and Mrukowicz J, Aliment Pharmacol Ther 2005 Sep 1; 22 (5): 365-72). (Szajewska H and Mrukowicz J, Aliment Pharmacol Ther 2005 Sep 1; 22 (5): 365-72).

The medicinal yeast has the additional advantage that - unlike the so-called probiotics - its effects are not inhibited when taken simultaneously with an antibiotic, since it has natural resistance to antibiotics (Czerucka D et al., Aliment Pharmacol Ther 2007 Sep 15; 26 (6): 767-78). KFN 1/2016 - 14.1.2016

Author and source information

Video: IBS Awareness Month Qu0026A w. Dr. Mark Pimentel. Cedars-Sinai